Dystonia is a movement disorder characterized by sustained or intermittent muscle contractions that cause abnormal, often repetitive, movements or postures. It can affect a single body part — such as the neck (cervical dystonia) or hand — or spread across multiple regions. Severity ranges from mild inconvenience to severe disability, and the underlying causes span genetic, neurological, and acquired factors.
What's actually going on in research
Botulinum toxin injections remain the front-line treatment for focal dystonias and are well established. Deep brain stimulation (DBS) of the globus pallidus is now standard care for medically refractory generalized dystonia and is being refined with new targets and closed-loop systems. Research is actively exploring gene therapy for monogenic forms such as DYT1, as well as non-invasive brain stimulation techniques and oral medications targeting the basal ganglia circuits responsible for abnormal muscle activity.
Deep brain stimulation advances
Next-generation DBS devices with directional leads and adaptive closed-loop stimulation are being tested to improve outcomes and reduce side effects in generalized and cervical dystonia.
Gene therapy for DYT1
Preclinical and early human studies are evaluating AAV-based gene therapy approaches targeting the TOR1A gene mutation responsible for DYT1 early-onset generalized dystonia.
Non-invasive brain stimulation
Transcranial magnetic stimulation and focused ultrasound are being investigated as non-surgical options for focal dystonias, with trials assessing optimal stimulation targets and session frequency.
What to know before you search
Eligibility varies by dystonia subtype, prior botulinum toxin use, surgical candidacy, and whether a causative genetic mutation has been identified.
What types of trials are currently open
- DBS device trials — Testing adaptive and directional deep brain stimulation systems in generalized and focal dystonia.
- Gene therapy trials — Early-phase studies evaluating AAV-based gene delivery for monogenic DYT1 and related dystonias.
- Non-invasive stimulation trials — Assessing TMS and focused ultrasound for cervical dystonia and task-specific dystonias.
- Botulinum toxin optimization — Comparing dosing, injection techniques, and formulations for focal and segmental dystonia.
- Oral medication trials — Testing basal ganglia-targeting drugs and muscle relaxants to complement or replace injections.
Recently added Dystonia trials
Brain Network Changes After Vibro-tactile Stimulation in Laryngeal Dystonia
Laryngeal dystonia (LD) is a focal dystonia affecting laryngeal muscles, causing involuntary spasms that impair speech production. Recent research demonstrated that non-invasive vibrotactile stimulation (VTS) of the laryngeal area can provide acute symptom relief in up to 57% of patients, with improvements in voice quality and reductions in perceived speech effort lasting from minutes to several days. However, the neural mechanisms underlying this therapeutic effect and the factors determining individual treatment response remain incompletely understood. The objective is to evaluate the acute effects of VTS on voice and speech parameters in participants with LD while characterizing associated changes in brain resting-state networks using magnetic resonance imaging (MRI).
LIFUS For Neurological Disorders
Low intensity focused ultrasound (LIFUS) has the potential to be used as a means of non-invasive neuro-modulation. To this day, the use of LIFUS is under investigation. Studies in healthy subjects have shown that application of LIFUS to the motor region of the brain can mildly decrease neuron excitability in healthy controls. The purpose of the present study is to evaluate the effects of LIFUS on brain tissue excitability in patients with movement disorders in order to elucidate the therapeutic potential of LIFUS.
Find Dystonia trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.